Prelude Therapeutics, Inc. (PRLD)

3.94 +0.06 (+1.68%) USD  |  NASDAQ  |  Sep 28, 15:01
More

Prelude Therapeutics Cash from Operations (Annual) : -56.30M for Dec. 31, 2025

Cash from Operations (Annual) Chart

View Cash from Operations (Annual) for PRLD.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Annual) Chart
Start Trial

Historical Cash from Operations (Annual) Data

View and export this data back to 2018. Start Trial.
Date Value
December 31, 2025 -56.30M
December 31, 2024 -102.89M
December 31, 2023 -107.06M
December 31, 2022 -83.73M
Date Value
December 31, 2021 -83.53M
December 31, 2020 -46.18M
December 31, 2019 -25.66M
December 31, 2018 -12.95M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Annual) Range, Past 5 Years

View Cash from Operations (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Annual) Benchmarks

View Cash from Operations (Annual) Benchmarks
Start Trial
Q32 Bio, Inc. -33.54M
Intellia Therapeutics, Inc. -394.74M
Twist Bioscience Corp. -47.63M
Beam Therapeutics, Inc. -345.10M
Revolution Medicines, Inc. -897.74M